Wegovy pill reaches UK patients as doctors debate prescribing and demand
The UK's first GLP-1 pill for weight loss is now on sale privately, giving patients an injection-free option that comes with strict daily fasting rules and no NHS coverage yet.
The semaglutide (Wegovy) tablet is now available to UK patients for weight loss, weeks after the Medicines and Healthcare Products Regulatory Agency authorized it, and its arrival has prompted debate among doctors about prescribing, monitoring and demand [1].
The MHRA approved the tablet on 11 June 2026, describing it as the UK's first GLP-1 receptor agonist tablet for weight loss and weight management [2]. It is licensed for adults with obesity and a BMI of 30 or above, or for adults who are overweight with a BMI between 27 and 30 and have at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity [1][2]. Until now, semaglutide had been available in the UK for weight loss only as an injection; the same molecule is already approved there as Rybelsus for type 2 diabetes [1].
How the tablet is taken
The starting dose is 1.5 mg once daily, increasing to 4 mg, 9 mg and 25 mg, with a minimum of one month at each dose level [2]. Patients already treated privately with a 2.4 mg semaglutide injection once a week can move straight to semaglutide 25 mg tablets once daily [2].
The tablet must be swallowed whole on an empty stomach after fasting for at least eight hours, with a sip of water, and no food or drink for at least 30 minutes afterward. Eating or drinking sooner lowers how much of the drug the body absorbs [2]. The most common side effects are gastrointestinal problems including nausea, diarrhea, constipation and vomiting [2].
"Having met the MHRA's rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management," said Julian Beach, executive director of healthcare quality and access at the MHRA. "As with all GLP-1 receptor agonists, this is a prescription-only medication" [2].
Access and cost
The pill is available privately, meaning patients buy it from high street pharmacies and online chemists [1]. It is not yet accessible on the NHS, because it first needs to be evaluated by the National Institute for Health and Care Excellence for cost effectiveness [1][2]. The MHRA said decisions on NHS use will follow established processes, including that NICE evaluation, and that the Summary of Product Characteristics and Patient Information leaflets were due to be published on the MHRA products website within seven days of approval [2].
The BMJ, which published its report on 7 July 2026, framed the launch around how the pill will affect doctors, noting questions about prescribing, monitoring and demand [1].
Why it matters for patients
An oral GLP-1 option changes the practical shape of treatment. A daily pill avoids injections, but it comes with a narrower set of rules than an injectable: an eight-hour fast before the dose and a 30-minute wait before eating or drinking, or absorption drops [2]. For people whose schedules make that routine hard, the pill may be less convenient than a weekly injection, even though it is not a needle.
Access is the other difference. In the UK, the tablet is currently a private purchase, so patients pay out of pocket rather than having it covered by the NHS while NICE reviews it [1][2]. An oral semaglutide product for weight loss has not been reported as approved in the United States, and the MHRA notes that this authorization applies to the UK [2].
Monitoring matters because the drug is prescription-only and carries common gastrointestinal side effects [2]. The MHRA says anyone who suspects a side effect should speak to a doctor, pharmacist or nurse and report it directly to the agency's Yellow Card scheme [2]. The MHRA added that it keeps the safety and effectiveness of semaglutide under close review [2].
What happens next
The next milestone is the NICE evaluation that would determine whether the tablet becomes available on the NHS; no date for that review has been reported [1][2]. Novo Nordisk, which makes Wegovy, received the authorization for the new weight-loss indication on 11 June 2026 [2]. The MHRA said the product's Summary of Product Characteristics and Patient Information leaflets would appear on its products website within seven days of approval [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.